Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking

Biomaterials

Volumn 33, Issue 9, 2012, Pages 2780-2790

  Li, Jin Ming ^a   Wang, Yuan Yuan ^a,b   Zhao, Mei Xia ^a   Tan, Cai Ping ^a   Li, Yi Qun ^b   Le, Xue Yi ^c   Ji, Liang Nian ^a   Mao, Zong Wan ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

CD; Co delivery; Doxorubicin; Multidrug resistance; QDs; SiRNA

Indexed keywords

CO-DELIVERY; DOXORUBICIN; MULTIDRUG RESISTANCE; QDS; SIRNA;

AMINO ACIDS; CELLS; CONFOCAL MICROSCOPY; DRUG THERAPY; GLYCOPROTEINS; HYDROPHOBICITY; POLYMERASE CHAIN REACTION; SEMICONDUCTOR QUANTUM DOTS;

GENE THERAPY;

BETA CYCLODEXTRIN ARGININE QUANTUM DOT; BETA CYCLODEXTRIN HISTIDINE QUANTUM DOT; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; QUANTUM DOT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ANALYSIS; HELA CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LASER MICROSCOPY; MULTIDRUG RESISTANCE; NANOENCAPSULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATIC ELECTRICITY; WESTERN BLOTTING;

ADSORPTION; CELL SHAPE; CELL TRACKING; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HELA CELLS; HUMANS; INTRACELLULAR SPACE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; P-GLYCOPROTEIN; PARTICLE SIZE; QUANTUM DOTS; RNA, SMALL INTERFERING; SPECTROMETRY, FLUORESCENCE; STATIC ELECTRICITY; TIME FACTORS;

EID: 84862815497     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.12.035     Document Type: Article

References (24)

1. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 50:63-68.
2. Aszalos A., Ladanyi A., Bocsi J., Szende B. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. Cancer Lett 2001, 167:157-162.
3. Ta H.T., Dass C.R., Larson I., Choong P.F., Dunstan D.E. Achitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 2009, 30:4815-4823.
4. Huang C., Li M., Chen C., Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008, 12:637-645.
5. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Codelivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
6. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 2008, 3:761-776.
7. Elbayoumi T.A., Torchilin V.P. Cancer-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic cancer in mice. Mol Pharm 2009, 6:246-254.
8. Kaneshiro T.L., Lu Z.R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 2009, 30:5660-5666.
9. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
10. Cao N., Cheng D., Zou S., Ai H., Gao J., Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011, 32:2222-2232.
11. Li J.M., Zhao M.X., Su H., Wang Y.Y., Tan C.P., Ji L.N., et al. Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging. Biomaterials 2011, 32:7978-7987.
12. Zhao M.X., Li J.M., Du L., Tan C.P., Xia Q., Mao Z.W., et al. Targeted cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with β-cyclodextrin coupled to amino acids. ChemEur J 2011, 17:5171-5179.
13. Zhao M.X., Xia Q., Feng X.D., Zhu X.H., Mao Z.W., Ji L.N., et al. Synthesis, biocompatibility and cell labeling of L-arginine-functional beta-cyclodextrin-modified quantum dot probes. Biomaterials 2010, 31:4401-4408.
14. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. Invivo drug delivery. JPharm Sci 1996, 85:1142-1169.
15. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004, 3:1023-1035.
16. Mirski S.E.L., Gerlach J.H., Cole S.P.C. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987, 47:2594-2598.
17. Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., et al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel pesistance with two cell lines. Prostate 2007, 67:955-967.
18. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. JPathol 2005, 205:275-292.
19. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian-cell lines. Nature 1985, 316:817-819.
20. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human " mdr1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987, 84:3004-3008.
21. Dönmez Y., Akhmetova L., Işeri ö.D., Kars M.D., Gündüz U. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol 2011, 67:823-828.
22. Shukla S., Wu C.P., Ambudkar S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008, 4:205-223.
23. Ferry D.R., Traunecker H., Kerr D.J. Clinical trials of P-glycoprotein reversal in solid cancers. Eur J Cancer 1996, 32:1070-1081.
24. Wang E., Casciano C.N., Clement R.P., Johnson W.W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001, 18:800-806.